Immunogenic β-amyloid peptide

Details Immunogenic β-amyloid peptide Immunogenic β-amyloid peptide

2005-03-01

2005-03-01

Kemmerer, Elizabeth (Department: 1647)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

C530S300000, C530S326000, C424S185100, C514S002600

Reexamination Certificate

active

06861057

ABSTRACT:
Frameshift Mutants β-Amyloid precursor peptides and mutant ubiquitin-B associated with Alzheimer's disease and Down syndrome eliciting T cellular immunity for use in compositions for the treatment and/or prophylaxis of Alzheimer's disease and/or Down syndrome.

REFERENCES:
patent: 5780587 (1998-07-01), Potter
patent: 5851996 (1998-12-01), Kline
patent: 5958684 (1999-09-01), Van Leeuwen et al.
patent: WO 9214756 (1992-09-01), None
patent: WO 9532731 (1995-12-01), None
patent: WO 9712992 (1997-04-01), None
patent: WO 9845322 (1998-10-01), None
patent: WO 9958552 (1999-11-01), None
patent: WO 0140804 (2001-06-01), None
patent: WO 0142306 (2001-06-01), None
Skolnick and Fetrow (2000) From Genes to Protein Strucuture and Function: Novel Applications of Compuational Approaches in the Genomic Era. Trends in Biotech 18(1); 34-39.*
Jobling et al. (1991) Analysis of structure and function of the B subunit of cholera toxin by the use of site-directed mutagenesis. Mol. Microbiol. 5(7):1755-67.*
Monsonego et al. (2001) Immune Hyporesponsiveness to amyloid beta-peptide in amyloid precursor protein transgenic mice: Implicaitons for the pathogenesis and treatment of Alzheimer's disease. PNAS 98(18): 10273-10278.*
DeMattos et al. (2001) “Peripheral Anti Abeta Antibody Alters CNS and Plasma Abeta Clearance and Decreases Brain Abeta Bruden in a Mouse Model of Alzheimer's Disease” PNAS 10: 1-6.*
Esiri (2001) Is an Effective Immune Intervention for Alzheimer's Disease in Prospect? Trends in Pharm Science 22(1): 2-3.*
Younkin (2001) Amyloid beta Vaccination: Reduced Plaques and Improved Cognition. Nature Medicine 7(1):18-19.*
Games et al. (1995) Alzheimer-type Neuropathology in Transgenic Mice Overexpressing V717F beta-amyloid precursor protein. Nature 373(6514): 523-527.*
Schenk et al. (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP Mouse. Nature 400:173-177.*
Small et al. (2001) Alzheimer's Disease and Abeta Toxicity: from top to bottom. Nat Rev Neurosci. 2(8): 595-8.*
Chapman (2000) Model Behavior. Nature 408: 915-916.*
Grubeck-Lobenstein et al. (2000) Immunization of beta-amyloid: could T-cell activation have a harmful effect? TINS 23: 114.*
Friedland et al. (1997) Neuroimaging of Vessel Amyloid in Alzheimer's Disease in Cerebrovascular Pathology in Alzheimer's Disease, eds. de la Torre and Hachinski, New York Academy of Science, NY, NY.*
Frenkel et al. (1998) N-terminal EFRH Sequence of Alzheimer's beta-amyloid peptide represents the epitope of its anti-aggregating antibodies. Journal of Neuroimmunology 88: 85-90.*
Frenkel et al. (2000) Immunization against Alzheimer's beta-amyloid plaques via EFRH phage adminstration. PNAS 97(21) 11455-11459.*
Frenkel et al. (1999) High Affinity Binding of Monoclonal Antibodies to the sequential epitope EFRH of beta-amyloid peptide is essential for modulation of fibrillar aggregation. Journal of Neuroimmunology 95: 136-142.*
ELAN “Elan and AHP Provide an Update on the Phase 2A Clinical Trial of AN-1792.” Press Release (Jan. 28, 2002) and ELAN “Elan and Wyeth Provide Update on Status of Alzheimer's Collaboration” Press Release (Mar. 1, 2002).*
Tanaka et al. (1998) NC-1900, an active Fragment analog of arginine vasopressin, improves learning and memory deficits induced by beta-amyloid protein in rats. European Journal of Pharmacology 352: 135-142.*
Tennet et al. (1995) Serum amyloid P component precents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. PNAS 92: 4299-4303.*
Chen et al. (1998) Neurodegenerative Alzheimer-like pathology in PDAPP 717V—F transgenic mice. Progress in Brain Research 117: 327-334.*
van Leeuwen et al., ( Jan., 1998), Science 279:242-247, “Frameshift Mutants of β Amyloid Precursor Protein and Ubiquitin-B in Alzheimer's and Down Patients”.
Vogel, (1998), Science 229:174, “Possible New Cause of Alzheimer's Disease Found”.
Gaudernack, (1996), Immunotechnology 2:3-9, “T cell responses against mutant ras: a basis for novel cancer vaccines”.
Gjertsen et al. (1996), Int. Jounal of Cancer 65:450-453, “Ex Vivo ras Peptide Vaccination in Patients with Advanced Pancreatic Cancer: Results of a Phase I/II Study”.
Gjertsen et al. (1997), Int. J. Cancer 72:784-790, “Cytotoxic CD4+and CD8+T-Lymphocyt s, Generated by Mutant p21-ras (12Val) Peptide Vaccination of a Patient, Recognize . . . Tumour Cells Carrying This Mutation”.
Gertsen et al. (1998) Vox Sanguinis 74(suppl. 2): 489-495, “Mutated Ras Peptides as Vaccines in Immunotherapy of Cancer”.
Terry et al., Alzheimer Disease, 1994, pp. 179-196, “Structural Basis of the Cognitiv Alterations in Alzheimer Disease”.
Barinaga, Science, vol. 257, 1992, pp. 880-881, “Getting Some Backbone”: How MHC Binds Peptides.
Deres et al., Nature, vol. 342, 1989, pp. 561-564, “In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine”.
Tighe et al., Immun. Today, vol. 19(2), 1998, pp. 89-97, “Gene vaccination: plasmid DNA is more than just a blueprint”.

Affiliated with

Also associated with

Rating

Immunogenic β-amyloid peptide does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Immunogenic β-amyloid peptide, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunogenic β-amyloid peptide will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3422140